Madan Jagasia is an Oncology physician affiliated with Barricaid. OpenAlex indexes 498 publications with 23,581 citations (h-index 70); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 Tvc
Nashville, TN 372320001
Telephone
615-322-3000Registry record last updated 12 Nov 2014.
Clinical trials
- Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
Sponsor: Vanderbilt-Ingram Cancer Center
- Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis
Sponsor: Vanderbilt-Ingram Cancer Center
- First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Sponsor: Vanderbilt-Ingram Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
1 NIH research award on record, funded 2020–2021 per NIH RePORTER. The latest:
- Translational Research and Interventional Oncology Research Program
Vanderbilt University Medical Center
FY2021$124,453P30CA068485 - Translational Research and Interventional Oncology Research Program
Vanderbilt University Medical Center
FY2020$124,453P30CA068485
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Journal for ImmunoTherapy of Cancer
2022 - Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Journal of Clinical Oncology
2021 - ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease
Journal of Clinical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”